An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data

[1] Coates LC(2016)Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis Arthritis Rheumatol. 68 1060-1071

[2] Kavanaugh A(2016)European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update Ann Rheum Dis 75 499-510

[3] Mease PJ(2008)Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics J Am Acad Dermatol. 58 851-864

[4] Soriano ER(2014)Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis Drugs. 74 423-441

[5] Acosta-Felquer ML(2016)Sulfasalazine: a rare cause of acute eosinophilic pneumonia Respir Med Case Rep. 18 35-36

[6] Armstrong AW(2010)Use of methotrexate in patients with psoriatic arthritis Clin Exp Rheumatol 28 S132-S137

[7] Gossec L(2004)Leflunomide-induced acute hepatitis Dig Liver Dis. 36 82-84

[8] Smolen JS(2010)Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis J Rheumatol 37 2205-2215

[9] Ramiro S(2016)Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis Expert Opin Drug Saf. 15 11-34

[10] de Wit M(2017)Tofacitinib or adalimumab versus placebo for psoriatic arthritis N Engl J Med 377 1537-1550

[1] Coates LC(2016)Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis Arthritis Rheumatol. 68 1060-1071

[2] Kavanaugh A(2016)European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update Ann Rheum Dis 75 499-510

[3] Mease PJ(2008)Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics J Am Acad Dermatol. 58 851-864

[4] Soriano ER(2014)Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis Drugs. 74 423-441

[5] Acosta-Felquer ML(2016)Sulfasalazine: a rare cause of acute eosinophilic pneumonia Respir Med Case Rep. 18 35-36

[6] Armstrong AW(2010)Use of methotrexate in patients with psoriatic arthritis Clin Exp Rheumatol 28 S132-S137

[7] Gossec L(2004)Leflunomide-induced acute hepatitis Dig Liver Dis. 36 82-84

[8] Smolen JS(2010)Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis J Rheumatol 37 2205-2215

[9] Ramiro S(2016)Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis Expert Opin Drug Saf. 15 11-34

[10] de Wit M(2017)Tofacitinib or adalimumab versus placebo for psoriatic arthritis N Engl J Med 377 1537-1550